Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health
December 2025
in “
Zenodo (CERN European Organization for Nuclear Research)
”
TLDR Post-drug syndromes are often overlooked, and better systems and education are needed to improve drug safety.
The policy brief addresses post-drug syndromes (PDS) as a neglected category of adverse drug reactions, highlighting conditions like Post-Finasteride Syndrome and Post-SSRI Sexual Dysfunction. It critiques current pharmacovigilance systems for focusing on acute adverse events, leading to under-recognition of long-term drug-induced harms. The brief identifies systemic failures, such as assumptions of reversibility and limitations in reporting systems, and proposes recommendations to improve drug safety oversight. These include recognizing PDS in pharmacovigilance, developing longitudinal reporting mechanisms, and integrating persistent adverse effects into medical education. The document aims to guide regulators and public health professionals in enhancing drug safety surveillance.